Relapsing Multiple Sclerosis, Ema Recommends Ocrelizumab Approval From 10 Years

Il Tempo

notizie.it

View article

newsbiella.it

View article

Rec News | Lontani dal mainstream

View article

canaledieci.it

View article

Giornale Radio

View article

+5 Reposted by 5 other sources

Right

Factuality

Ownership

Rome, 21 Sep. (Adnkronos Salute) - The Committee for Medicinal Products for Human Use (Chmp) of the European Medicines Agency (Ema) recommended the approval of ocrelizumab for intravenous infusion for the treatment of children and adolescents with multiple sclerosis from 10 years of age and older, suffering from recurrent forms of multiple sclerosis (Smr). This is announced in a note, Roche pointing out that the final decision by the European Co…

periodicodaily.com

Factuality

Ownership

The Committee for Medicinal Products for Human Use (Chmp) of the European Medicines Agency (Ema) recommended the approval of ocrelizumab for intravenous infusion for the treatment of children and adolescents with multiple sclerosis from 10 years of age and older with relapsed forms of multiple sclerosis (Smr). Roche announces this in a note highlighting [...]